T Cell Receptor Based Cell Therapy Articles & Analysis: This-Year
4 articles found
By administering recombinant chemokines, scientists can redirect immune cells to the tumor microenvironment, potentially enhancing the efficacy of checkpoint inhibitors or CAR-T cell therapies. For instance, CXCL10 has shown promise in preclinical models by enhancing T-cell infiltration into ...
Cancer treatment has witnessed transformative advancements over the past few decades, notably with the emergence of CAR-T (Chimeric Antigen Receptor T-cell) therapy. This revolutionary therapy harnesses the body's immune system by genetically engineering T-cells to target and destroy cancer cells. Among the pioneering companies at the forefront of this innovation is Alfa Cytology, renowned for ...
Alfa Cytology unveils advanced PD-1 inhibitor development service for cancer research. Alfa Cytology, a prominent service provider in the oncology landscape, has recently launched its innovative PD-1 inhibitor development services. This initiative marks a significant advancement in the quest for more effective cancer therapies, focusing on enhancing precision and adaptability in treatment ...
Leukemia, a malignant disorder of the blood and bone marrow, poses significant challenges to both patients and healthcare providers. Traditional treatments, including chemotherapy and radiation, while effective for some, often come with severe side effects and varied success rates. Enter immunotherapy - a groundbreaking approach that is not only redefining leukemia treatment but also offering ...